Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases

AIDS

Volumn 15, Issue 9, 2001, Pages 1133-1142

  Ghani, Azra C ^a   Henley, William E ^b   Donnelly, Christl A ^a   Mayer, Steven ^c   Anderson, Roy M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

Author keywords

AIDS; Antiretroviral therapy; HIV 1; Non nucleoside reverse transcriptase inhibitors; Observational databases; Protease inhibitors

Indexed keywords

CD4 ANTIGEN; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035875831     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00008     Document Type: Article

References (44)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients
3. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
4. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
6. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
7. The Atlantic study: A randomized, open-label study to evaluate the efficacy and safety of three triple combination therapies aimed at different HIV targets in antiretroviral naive HIV-1 infected patients (final 48 weeks analysis)
8. The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
9. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
10. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection
11. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults
12. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
13. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
14. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
15. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
16. Survival after introduction of HAART in people with known duration of HIV-1 infection
17. Clinical implications of antiretroviral resistance
18. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
19. Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA panel
20. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
21. Antiretroviral drug guidelines for the treatment of HIV infection - Should protease inhibitors always be included in the initial regimen or not?
22. High-quality clinical databases: Breaking down the barrier
23. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome
24. The central role of the propensity score in observational studies for causal effect
25. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance
26. Sample sizes based on the log-rank statistic in complex clinical trials
27. Sample size calculation for complex clinical trials with survival endpoints
28. Assessing the sensitivity of regression results to unmeasured confounders in observational studies
29. Letter
30. The unpredictability paradox: Review of empirical comparisons of randomised and non-randomised clinical trials
31. Which clinical studies provide the best evidence?
32. Randomized trials or observational tribulations?
33. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies
34. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials
35. Choosing between randomised and non-randomised studies: A systematic review
36. A comparison of observational studies and randomised controlled trials
37. Randomized, controlled trials, observational studies, and the hierarchy of research designs
38. Bias in treatment assignment in controlled clinical trials
39. Sources of bias must be controlled
40. The effectiveness of right heart catheterization in the initial care of critically ill patients
41. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
42. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population